Get the Stockscreener App
73.15
0.47%
0.34
Halozyme Therapeutics Inc stock is traded at $73.15, with a volume of 1.16M.
It is up +0.47% in the last 24 hours and up +23.88% over the past month.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
See More
Previous Close:
$72.81
Open:
$73
24h Volume:
1.16M
Relative Volume:
0.54
Market Cap:
$8.56M
Revenue:
$947.36M
Net Income/Loss:
$392.47M
P/E Ratio:
24.22
EPS:
3.02
Net Cash Flow:
$392.71M
1W Performance:
+1.85%
1M Performance:
+23.88%
6M Performance:
+26.78%
1Y Performance:
+14.76%
1-Day Range:
$72.47
$73.26
1-Week Range:
$71.91
$74.07
52-Week Range:
$42.01
$74.07
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Name
Halozyme Therapeutics Inc
Sector
Industry
Phone
(858) 794-8889
Address
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
73.15 | 8.52B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-10-25 | Resumed | Goldman | Neutral |
| May-14-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Downgrade | Leerink Partners | Market Perform → Underperform |
| Oct-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-19-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-07-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-29-24 | Initiated | TD Cowen | Outperform |
| Jul-24-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-24-23 | Initiated | H.C. Wainwright | Buy |
| May-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Berenberg | Buy |
| Mar-16-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Dec-21-22 | Resumed | Morgan Stanley | Overweight |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Initiated | Evercore ISI | Outperform |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-21-21 | Reiterated | The Benchmark Company | Buy |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jul-01-20 | Initiated | The Benchmark Company | Buy |
| Feb-05-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Buy |
| Nov-05-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-19-18 | Resumed | Piper Jaffray | Neutral |
| May-11-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Oct-16-17 | Reiterated | Piper Jaffray | Overweight |
| Jan-06-17 | Downgrade | Citigroup | Buy → Neutral |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Nov-18-15 | Initiated | Citigroup | Buy |
| Sep-22-15 | Initiated | Barclays | Overweight |
| Jun-22-15 | Reiterated | JP Morgan | Overweight |
| Mar-03-15 | Reiterated | UBS | Buy |
| Feb-18-15 | Reiterated | MLV & Co | Buy |
| Jan-08-15 | Reiterated | MLV & Co | Buy |
View All
Halozyme Therapeutics Inc Stock (HALO) Latest News
Will Halozyme Therapeutics Inc. outperform the marketTrade Exit Summary & Free Safe Entry Trade Signal Reports - Newser
Can a trend reversal in Halozyme Therapeutics Inc. lead to recoveryWeekly Gains Summary & Daily Stock Trend Watchlist - Newser
What’s next for Halozyme Therapeutics Inc. stock priceInsider Buying & Real-Time Volume Analysis Alerts - Newser
Halozyme Therapeutics Inc. recovery potential after sell off2025 Top Decliners & Daily Profit Focused Stock Screening - Newser
Real time social sentiment graph for Halozyme Therapeutics Inc.CEO Change & Long-Term Capital Growth Strategies - Newser
Applying big data sentiment scoring on Halozyme Therapeutics Inc.Bear Alert & Weekly High Potential Stock Alerts - Newser
Is Halozyme Therapeutics Inc. stock ready for a breakoutWeekly Trade Report & Weekly Breakout Watchlists - Newser
Analyzing net buyer seller activity in Halozyme Therapeutics Inc.2025 Big Picture & Short-Term High Return Strategies - Newser
What moving averages say about Halozyme Therapeutics Inc.Weekly Gains Summary & Verified Technical Signals - Newser
Halozyme Therapeutics Inc. stock volume spike explainedTrade Risk Assessment & Fast Gain Stock Tips - Newser
Leading vs lagging indicators on Halozyme Therapeutics Inc. performanceJuly 2025 Volume & Reliable Price Breakout Alerts - Newser
Forecasting Halozyme Therapeutics Inc. price range with options dataQuarterly Portfolio Report & Weekly Setup with ROI Potential - Newser
Analyzing drawdowns of Halozyme Therapeutics Inc. with statistical toolsPortfolio Risk Summary & Free Growth Oriented Trading Recommendations - Newser
What candlestick patterns are forming on Halozyme Therapeutics Inc.July 2025 Summary & Fast Momentum Entry Tips - Newser
Using data models to predict Halozyme Therapeutics Inc. stock movementGold Moves & AI Forecast for Swing Trade Picks - Newser
Trend analysis for Halozyme Therapeutics Inc. this weekPortfolio Update Report & Expert Curated Trade Ideas - Newser
Published on: 2025-08-30 15:51:14 - Newser
Real time pattern detection on Halozyme Therapeutics Inc. stockTrade Risk Summary & Free Growth Oriented Trading Recommendations - Newser
Halozyme Therapeutics Inc. stock outlook for YEAR2025 Historical Comparison & Risk Controlled Stock Pick Alerts - Newser
Ranking Halozyme Therapeutics Inc. among high performing stocks via tools2025 Price Targets & Smart Swing Trading Techniques - Newser
Halozyme (HALO) Q2 EPS Jumps 69% - AOL.com
What to expect from Halozyme Therapeutics Inc. in the next 30 daysMarket Growth Summary & AI Driven Stock Price Forecasts - Newser
Visual analytics tools that track Halozyme Therapeutics Inc. performanceEntry Point & High Accuracy Swing Trade Signals - Newser
Chart overlay techniques for tracking Halozyme Therapeutics Inc.Day Trade & Smart Allocation Stock Reports - Newser
Identify Superstar Stocks Like Halozyme with Money Flows - FXEmpire
Is a relief rally coming for Halozyme Therapeutics Inc. holdersJuly 2025 Final Week & Pattern Based Trade Signal System - Newser
Applying Wyckoff theory to Halozyme Therapeutics Inc. stockMarket Rally & Advanced Technical Signal Analysis - Newser
Will Halozyme Therapeutics Inc. announce a stock splitWeekly Investment Recap & Real-Time Chart Pattern Alerts - sundaytimes.kr
Halozyme Therapeutics’ ENHANZE Platform: A Catalyst for Sustained Revenue Growth - AInvest
Halozyme Therapeutics Inc Stock (HALO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Halozyme Therapeutics Inc Stock (HALO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
Aug 12 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Aug 13 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Aug 13 '25 |
Sale |
64.32 |
20,000 |
1,286,351 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Aug 12 '25 |
Sale |
63.51 |
20,000 |
1,270,121 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Aug 11 '25 |
Sale |
63.05 |
20,000 |
1,260,917 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Jul 08 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Jul 09 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Jul 10 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Jul 10 '25 |
Sale |
57.43 |
20,000 |
1,148,618 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Jul 09 '25 |
Sale |
56.43 |
20,000 |
1,128,655 |
733,719 |
0.96%
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):